ES2370225T3 - Anticuerpos superhumanizados. - Google Patents

Anticuerpos superhumanizados. Download PDF

Info

Publication number: ES2370225T3
Authority: ES; Spain
Prior art keywords: cdr; antibody; subject; variable region; human
Prior art date: 2002-07-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES02752269T

Other languages

English (en)

Spanish (es)

Inventor

Jefferson Foote

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-12

Filing date

2002-07-12

Publication date

2011-12-13

2002-07-12 Application filed by Individual filed Critical Individual

2002-07-12 Priority claimed from PCT/US2002/022011 external-priority patent/WO2004006955A1/en

2011-12-13 Application granted granted Critical

2011-12-13 Publication of ES2370225T3 publication Critical patent/ES2370225T3/es

2022-07-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 claims abstract description 94
125000000539 amino acid group Chemical group 0.000 claims abstract description 31
238000004519 manufacturing process Methods 0.000 claims abstract description 9
241000282414 Homo sapiens Species 0.000 claims description 274
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 126
101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 claims description 90
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 53
108090000623 proteins and genes Proteins 0.000 claims description 53
239000000427 antigen Substances 0.000 claims description 52
108091007433 antigens Proteins 0.000 claims description 51
102000036639 antigens Human genes 0.000 claims description 51
210000004602 germ cell Anatomy 0.000 claims description 30
150000001413 amino acids Chemical class 0.000 claims description 24
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 23
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 23
150000007523 nucleic acids Chemical class 0.000 claims description 8
238000010494 dissociation reaction Methods 0.000 claims description 7
230000005593 dissociations Effects 0.000 claims description 7
230000008569 process Effects 0.000 claims description 6
230000009471 action Effects 0.000 claims description 5
210000004027 cell Anatomy 0.000 claims description 5
102000039446 nucleic acids Human genes 0.000 claims description 4
108020004707 nucleic acids Proteins 0.000 claims description 4
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 3
241000699666 Mus <mouse, genus> Species 0.000 description 39
101100112922 Candida albicans CDR3 gene Proteins 0.000 description 28
241001529936 Murinae Species 0.000 description 26
235000001014 amino acid Nutrition 0.000 description 22
108090000765 processed proteins & peptides Proteins 0.000 description 21
101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 19
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 19
102000054751 human RUNX1T1 Human genes 0.000 description 19
241000894007 species Species 0.000 description 15
238000010276 construction Methods 0.000 description 12
125000003275 alpha amino acid group Chemical group 0.000 description 11
230000005847 immunogenicity Effects 0.000 description 11
241000282412 Homo Species 0.000 description 10
102000008214 Glutamate decarboxylase Human genes 0.000 description 8
108091022930 Glutamate decarboxylase Proteins 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
238000013459 approach Methods 0.000 description 8
239000012634 fragment Substances 0.000 description 8
210000004408 hybridoma Anatomy 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
108060003951 Immunoglobulin Proteins 0.000 description 7
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
102000018358 immunoglobulin Human genes 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
239000000126 substance Substances 0.000 description 7
235000010335 lysozyme Nutrition 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
239000002795 scorpion venom Substances 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
102000016943 Muramidase Human genes 0.000 description 5
108010014251 Muramidase Proteins 0.000 description 5
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
101150117115 V gene Proteins 0.000 description 5
210000000628 antibody-producing cell Anatomy 0.000 description 5
229960000274 lysozyme Drugs 0.000 description 5
239000004325 lysozyme Substances 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000006872 improvement Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
108020004414 DNA Proteins 0.000 description 3
101150008942 J gene Proteins 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000035772 mutation Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
229960000598 infliximab Drugs 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000035800 maturation Effects 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
206010002198 Anaphylactic reaction Diseases 0.000 description 1
101150040566 B3 gene Proteins 0.000 description 1
208000031872 Body Remains Diseases 0.000 description 1
102000004031 Carboxy-Lyases Human genes 0.000 description 1
108090000489 Carboxy-Lyases Proteins 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101100332755 Mus musculus Edar gene Proteins 0.000 description 1
101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
101710149951 Protein Tat Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009933 burial Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001506 fluorescence spectroscopy Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000011268 retreatment Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000000547 structure data Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1

Landscapes

Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ES02752269T 2002-07-12 2002-07-12 Anticuerpos superhumanizados. Expired - Lifetime ES2370225T3 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2002/022011 WO2004006955A1 (en)	2001-07-12	2002-07-12	Super humanized antibodies

Publications (1)

Publication Number	Publication Date
ES2370225T3 true ES2370225T3 (es)	2011-12-13

Family

ID=43969199

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES02752269T Expired - Lifetime ES2370225T3 (es)	2002-07-12	2002-07-12	Anticuerpos superhumanizados.

Country Status (4)

Country	Link
AT (1)	ATE506966T1 (de)
DE (1)	DE60239895D1 (de)
DK (1)	DK1539233T3 (de)
ES (1)	ES2370225T3 (de)

2002
- 2002-07-12 AT AT02752269T patent/ATE506966T1/de active
- 2002-07-12 ES ES02752269T patent/ES2370225T3/es not_active Expired - Lifetime
- 2002-07-12 DK DK02752269.7T patent/DK1539233T3/da active
- 2002-07-12 DE DE60239895T patent/DE60239895D1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ATE506966T1 (de)	2011-05-15
DE60239895D1 (de)	2011-06-09
DK1539233T3 (da)	2011-08-08

Publication	Publication Date	Title
CN1671416B (zh)	2013-01-02	超人源化抗体
US20050288491A1 (en)	2005-12-29	Super-humanized antibodies against respiratory syncytial virus
US7456260B2 (en)	2008-11-25	Humanized antibody
TWI351407B (en)	2011-11-01	Method of humanizing immune system molecules
JP6744856B2 (ja)	2020-08-19	α−シヌクレインを認識する抗体を含む血液脳関門シャトル
US20190031770A1 (en)	2019-01-31	Intercalated single-chain variable fragments
US9550986B2 (en)	2017-01-24	High-throughput antibody humanization
KR20140125409A (ko)	2014-10-28	알파-시누클레인을 인식하는 인간화된 항체
JP2023518952A (ja)	2023-05-09	獣医用抗ｉｌ４受容体抗体
TW201134489A (en)	2011-10-16	Basigin binding proteins
WO2018235247A1 (ja)	2018-12-27	抗ｃｄ１０抗体
WO2019079762A1 (en)	2019-04-25	METHODS OF DISCOVERING ANTIBODIES USING TRANSCRIPTOMES AND COMPOSITIONS DERIVED THEREFROM
CN101962408A (zh)	2011-02-02	超人源化抗体
JP7607289B2 (ja)	2024-12-27	新規の抗ｂ型肝炎ウイルス抗体及びその使用
ES2370225T3 (es)	2011-12-13	Anticuerpos superhumanizados.
JP2023508366A (ja)	2023-03-02	二重特異性ｆｃｙｒｉｉｉ×ｃｄ３０抗体構築体の製造方法
Mader et al.	2010	Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41
WO2024006975A1 (en)	2024-01-04	Methods for antibody humanization
JP2011115175A (ja)	2011-06-16	スーパーヒト化抗体
JP2012152223A (ja)	2012-08-16	スーパーヒト化抗体
JT George et al.	1996	Section Review Biologicals & Immunologicals: Advances in antibody engineering
Marks	1996	Selection of Human Antibody Fragments which Bind Novel Breast Tumor Antigens
Holm	2005	Single-chain antibody construction and functional mapping of the monoclonal antibody TS1: Its interaction with the antigen and the anti-idiotype